Biologics Engineering - Technology Development Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Alexion Pharmaceuticals, Inc. · 13 hours ago

Biologics Engineering - Technology Development Intern

positionGaithersburg, Maryland, United States of America
timeInternship
remoteOnsite
seniorityIntern
money$37/hr - $39/hr

Alexion Pharmaceuticals, Inc. is seeking undergraduate junior and senior level students for a 12-week internship in Biologics Engineering. The role involves driving innovative research on engineered antibodies and conducting quality control and in vitro assays.

BiotechnologyHealth CareMedicalTherapeutics
check
Comp. & BenefitsbadNo H1Bnote

Responsibilities

Drive innovative research on the development of engineered bispecific/multi-specific antibodies
Conduct molecule quality control, utilizing techniques such as LCMS and antigen binding validation by octet
Hone technical skills in conducting in vitro assays, specifically T cell expansion, and proliferation assay

Qualification

Wet lab skillsMolecular engineeringCloningFlow cytometryTissue cultureVitro assaysT cell expansionProliferation assay

Required

Undergraduate junior and senior level students majoring in Biology, Biomedical Engineering, or a related discipline. Candidates must have an expected graduation date after August 2026
Wet lab skills required, such as: cloning, basic flow cytometry, molecular engineering, tissue culture, etc
Ability to report onsite to Gaithersburg, MD 3-5 days per week. This role will not provide relocation assistance
US Work Authorization is required at time of application
This role will not be providing CPT support

Company

Alexion Pharmaceuticals, Inc.

twittertwittertwitter
Glassdoor3.9
company-logo
Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community.
dateFounded in 1992
location
Boston, Massachusetts, USA
people-size1001-5000 employees
web-link
https://alexion.com

Funding

Current Stage
Public Company
Total Funding
$5.8M
2020-12-12Acquired
1999-02-12Post Ipo Equity· $5.8M
1996-02-29IPO

Leadership Team

leader-logo
Frederic Chereau
SVP, Strategy and Business Development
linkedin
leader-logo
Imran Shakur
Director, IRT and Technology Lead
linkedin

Recent News

BioWorld Financial Watch
Alexion Pharmaceuticals discloses C1S inhibitors
2026-01-17
bloomberglaw.com
AstraZeneca Unit Gets Partial Win in Soliris Drug Monopoly Case
2025-12-20
Business Wire
Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline and Competitive Intelligence Report 2025 - ResearchAndMarkets.com
2025-12-01
Company data provided by crunchbase